PharVision Advisers’s Hinge Health HNGE Stock Holding History

PharVision Advisers’s Portfolio HNGE Stock Details HNGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,983	Closed	-$417K	–	697
2025 Q4	$417K	Buy	+8,983	New	+$433K	0.21%	103

Other funds holding HNGE

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

11.2 Capital Management Las Vegas, Nevada $143M AUM

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fuller & Thaler Asset Management

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

American Century Companies

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PharVision Advisers's HNGE Position: Q1 2026 in Review

PharVision Advisers sold out of Hinge Health (HNGE) in Q1 2026, closing a stake of 8,983 shares — an estimated $417K sold.

PharVision Advisers first reported a position in HNGE in Q4 2025 and held it in 1 quarter. The position peaked at $417K in Q4 2025. 203 funds tracked by Wall St. Rank hold HNGE as of Q1 2026.

PharVision Advisers reported no remaining Hinge Health position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 8,983 Hinge Health shares in Q1 2026, an estimated $417K.
PharVision Advisers first reported a position in Hinge Health in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Hinge Health position peaked at $417K in Q4 2025.
203 funds tracked by Wall St. Rank held Hinge Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.